The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor by unknown
The Human Peripheral Lymph Node Vascular Addressin Is a Ligand for
LECAM4, thePeripheral Lymph Node Homing Receptor
EllenL. Berg, MartynK. Robinson, R. Aaron Warnock, and Eugene C. Butcher
Department ofPathology, Stanford University, Stanford, California 94305 ; and The Center for Molecular Biology and Medicine,
The Veterans Administration Medical Center, Palo Alto, California 94304
Abstract. The trafficking of lymphocytes from the
blood and into lymphoid organs is controlled by tissue-
selective lymphocyte interactions with specialized endo-
thelial cells lining post capillary venules, in particular
the high endothelial venules (HEV) found in lymphoid
tissues and sites of chronic inflammation. Lymphocyte
interactions with HEV are mediated in part by lym-
phocyte homing receptors and tissue-specific HEV de-
terminants, the vascular addressins. A peripheral lymph
node addressin (PNAd) has been detected immunohis-
tologically in mouse and man by monoclonal antibody
MECA79, which inhibits lymphocyte homing to lymph
nodes and lymphocyte binding to lymph node and ton-
sillar HEV The human MECA-79 antigen, PNAd, is
molecularly distinct from the 65-kD mucosal vascular
ADHESION to endothelial cells initiates the process of DH A lymphocyte entrance into lymphoid organs and is
also one of the initial events in lymphocyte recruit-
ment into tissues at sites of inflammation. Lymphocytes are
unique among leukocytes in that they continuously traffic be-
tween the blood and lymphatic systems, entering lymphoid
organs by adhering to specialized high-walled venules known
as high endothelial venules (HEV)' (Gowans and Knight,
1964; Marchesi and Gowans, 1964). They exit lymph nodes
through efferent lymphatics, passing back to the blood via
the thoracic duct. HEV are found preferentially in lymphoid
organs and in sites of chronic inflammation . Specific lym-
phocyte and endothelial cell receptors are thought to mediate
the adhesion process, and thus control the type of cells re-
cruited into lymphoid organs and inflammatory sites.
Lymphocyte interactions with HEV are characteristically
tissue specific. Lymphocyte subsets have the capacity to dis-
tinguish between HEV in peripheral lymph nodes, mucosal
lymphoid tissues, the chronically inflamed synovium of ar-
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1. Abbreviations used in this paper: CM, complete medium; HEV, high en-
dothelial venules; MAd, mucosal addressin; PBMC, peripheral blood
mononuclear cells ; PLN, peripheral lymph node; PNAd, peripheral lymph
node addressin.
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addressin. The most abundant iodinated species by
SDS-PAGE is 105 kD. When affinity isolated and im-
mobilized on glass slides, MECA-79 immunoisolated
material binds human and mouse lymphocytes avidly
in a calcium dependent manner. Binding is blocked by
mAb MECA-79, by antibodies against mouse or hu-
man LECAM-1 (the peripheral lymph node homing re-
ceptor, the MEL-14 antigen, LAM-1), and by treatment
of PNAd with neuraminidase. Expression of LECAM-1
cDNA confers PNAd binding ability on a transfected
B cell line. We conclude that LECAM-1 mediates lym-
phocyte binding to PNAd, an interaction that involves
the lectin activity of LECAM-1 and carbohydrate de-
terminants on the addressin .
thritic joints, and chronically inflamed skin (reviewed in
Butcher et al ., 1980; Jalkanen et al., 19866; Berg et al.,
1989; Chin et al., 1988). This capacity is controlled in part
by lymphocyte expression of "homing receptors" for particu-
lar HEV and by endothelial cell expression oftissue-specific
"vascular addressins" (Streeter et al., 1988a,b ; Berg et al .,
1989).
One of the best characterized lymphocyte homing recep-
tors is involved in lymphocyte recognition of peripheral
lymph node HEV Antibodies to the peripheral lymph node
(PLN) homing receptor, LECAM-1, blocklymphocyte bind-
ing to PLN HEV and not Peyer's patch HEV, and selectively
recognize PLN-HEV binding lymphocytes and lymphocyte
cell lines(Gallatin etal., 1983) . The expression ofLECAM-1
is regulated during lymphocyte development, and after acti-
vation of lymphocytes in vivo, helps determine the capacity
ofdefined virgin versus memory lymphocyte subpopulations
to recirculate through peripheral lymph nodes (Butcher,
1986; Picker et al., 19896). LECAM-1 is a member of the
LEC-CAM or selectin gene family (reviewed in Stoolman,
1989) and appears to function as a lectin capable of binding
in a neuraminidase sensitive-mechanism to PLN HEV (Imai
et al., 1990) .
The peripheral lymph node vascular addressin also plays
a role in lymphocyte binding to PLN HEV (Streeter et al.,
19886, 1991). The vascular addressins are tissue-specific de-
343terminants on high endothelial venules which direct ex-
travasating lymphocytes into the appropriate lymphoid or
extralymphoid tissues (Streeter et al., 1988a,b; reviewed in
Berg et al., 1989). The peripheral lymph node addressin
(PNAd), defined by monoclonal antibody MECA-79, is a
tissue-specific endothelial cell antigen foundon HEV in both
mouse and man (Streeter et al., 19ß8b, 1991). Immunohisto-
logic studies in the mouse reveal that MECA-79 stains PLN
HEV, and a major subset ofmesentericnode HEV intensely,
but in most mouse strains reacts only weakly with HEV in
the mucosal lymphoid organs, the Peyer's patches. Vessels
that support lymphocyte extravasation into the small intesti-
nal lamina propria, which express the mucosal addressin
(MAd), completely lack the MECA-79 antigen. In humans,
HEV in PLN, tonsils, and some sites of extralymphoid
chronic inflammation react with mAb MECA-79 (Streeter et
al., 1991). Lamina propria venules in the small intestine are
negative, as in the mouse, but HEV in the mucosal lymphoid
tissues (Peyer's patches and appendix) stain with MECA-79,
albeit less intensely than HEV in lymph nodes. In both spe-
cies, mAb MECA-79 inhibits lymphocyte binding to PLN
HEV, but not substantially to HEV in mouse Peyees patches
or human appendix, in which binding via the mucosal ad-
dressin predominates (Streeter et al., 19ß8b, 1991) .
The present studies were undertaken to characterize hu-
man PNAd; to ask ifit binds lymphocytes directly, or instead
directs lymphocyte traffic to PLN by other means; to assess
the importance of carbohydrate to its function; and ask
whether it is the countereceptor for the lymphocyte PLN
homing receptor, LECAM-1.
Materials andMethods
Immunoisolation ofPNAd
PNAd (the MECA-79 antigen), and control membrane glycoproteins
LECAM-1 and H-CAM (the Hermes antigen or CD44; Jalkanen et al.,
19ß6a) were isolated from human tonsils using a two-step procedure.
Briefly, NP-40 tissue extracts were prepared as previously described
(Streeter et al., 19ß8a; Nakache et al., 1988), then passed over wheat germ
agglutinin-coupled agarose columns (Vector Labs, Inc., Burlingame, CA).
Material eluting with 0.5 M N-acetylglucosamine was then passed sequen-
tially through 2 ml affinity columns of rat IgM mAb control and Hermes-1
(anti-H-CAM or CD44) (Jalkanen et al., 19ß6a), or DREG-56 (anti-
LECAM-1) (Kishimoto et al., 1990), and then MECA-79 coupled to
Sepharose 4B (Pharmacia Inc., Piscataway, NJ). The column wash and elu-
tionconditions with ß-octylglucoside-containing wash buffer were as previ-
ously described for the isolation and functional reconstitution of the
mucosal addressin (Nakache et al., 1988). To assess the purity, an aliquot
ofeach of the column eluates was iodinatedby standard methods (Indogen;
Pierce Chemical Co., Rockford, IL), desalted to remove free iodine, and
analyzed by SDS-PAGE followed by autoradiography. Samples run on SDS-
PAGE and stained with silver show the same pattern of species (data not
shown). Western blots on immunoisolated PNAd were performed as previ-
ously described (Streeter et al., 1988x), except that the second stage used
wasalkaline phosphatase-conjugated rabbit anti-rat IgG (H+L) from Tago,
Inc. (Burlingame, CA). Preliminary studies with Western analysis
confirmed that all detectable MECA-79-reactive species in tissue lysates
were bound by wheat germ agglutinin.
BindingofLymphocytesand CellLinestoPNAd
Samples ofhumanPNAdor control proteins were absorbedonto glass wells
ofslides (LABTEK, Wilmington, MA) by dilution in Dulbeccds modified
Eagles medium (DMEM; Applied Scientific, SanFrancisco, CA), followed
by a2-h incubation at roomtemperature. After blocking with complete me-
dium (CM, 10 mM Hepes, 5% newborn calf serum [Gibco Laboratories,
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Grand Island, NY] in DMEM), human peripheralblood mononuclear cells
(PBMC), or PLN lymphocytes from normal BALB/c mice (1.5 x 106/0.15
ml CM) were applied to each well. After incubation for 20 min at room
temperature on a rotating shaker (50 rpm), the tops of the wells were re-
moved and the slides washed by dipping twice into coplin jar, of DMEM
and then fixedby incubation in 1.5 % glutaraldehyde (Kodak) in DMEM for
1 h. PBMC were preparedby 1 g sedimentationof redblood cells with Dex-
tran T500 (Pharmacia, Inc.) and thencentrifugation ofthe white blood cells
on Ficoll-histopaque (Histopaque 1077; Sigma Chemical Co., St. Louis,
MO) to separate mononuclear cells from polymorphonuclear leukocytes
and then 25 % Percoll (Pharmacia, Inc.) to remove residual platelets. Most
PNAd adherent cells were lymphocytes, as assessed morphologically and
by Wrights stain. Both human and mouse lymphocyte interactions with hu-
man PNAd were studied as the tissue specificity of lymphocyte-HEV inter-
actions is retainedacross speciesbarriers. (Mouselymphocytes and lympho-
cyte cell lines can bind to and discriminate between human PLN HEV and
appendix HEV withthe same specificity asdo human lymphocytes, and hu-
man lymphocytes adhere to murine PLN HEV and mucosal HEV via the
same distinct mechanisms as do mouse lymphocytes [Wu et al., 19881.)
Binding of cell lines was carried out as described for lymphocytes. The hu-
man JurkatJS-978 (Stoolmanand Ebling, 1989) and mouse 3ßC13 (Gallatin
et al., 1983)cell lines bind well to PLN HEV in frozen sections. The mouse
cell line Ll-2 does not bind either PLN or mucosal HEV; and mouse lines
TKl and TKI43 avidly bind mucosal HEV, but do not bind well to PLN
HEV (Butcher et al., 1980; Gallatinet al., 1983). Ll-2cells transfected with
mouse LECAM-1 cDNA, asdescribed below, were also tested. The amount
of PNAd added per well ranged from x+10-100 ng (roughly estimated from
comparison on silver-stained gels). In all ofthe studies presented here, the
amount ofPNAd added per well was limiting, as increasing the amount of
PNAd added per well led to increased lymphocyte attachment. In contrast,
increasingthe amountofcontrol proteinsadded to each well (either H-CAM
or LECAM-1) never resulted in lymphocyte attachment.
For some binding experiments, the wells containing PNAd were washed
andtreated either with mAbs MECA-79 or control rat IgM mAbHECA-452
(Duijvestijn et al., 1988) (200 jAg/ml in CM) for 30 min and then washed
in CM before the addition oflymphocytes. Alternatively, wells containing
PNAd were treated with Vibrio cholera neuraminidase 5 mU/ml (Calbio-
chem-Behring Corp., Palo Alto, CA) in 50 mM NaH2PO4, pH 6.0, 2 mM
CaC12 for 30 min before washing with CM and subsequent addition of lym-
phocytes. Similar results were obtained using the neuraminidase from Ar-
throbacter ureafaciens (data not shown).
The calcium dependence of the interaction of lymphocytes with PNAd
was tested by performing the assay with lymphocytes suspended in HBSS
without calcium or magnesium (Applied Scientific) containing 0.5 mM
EGTA or HBSS containing 0.5 mM EGTA and 5 mM CaC12.
To test anti-lymphocyte mAbs, human or mouse lymphocytes were
preincubated with 100 gg/ml/107 cells of the mAbs DREG-56 (anti-human
LECAM-1) (Kishimoto et al., 1990), Hermes-3 (anti-human H-CAM or
CD44) (Jalkanen et al., 1987), MEL-14 (anti-mouse LECAM-1) (Gallatin
et al., 1983), RI/2 (anti-mouse VLA-4 a chain, LPAM) (Holzmann et al.,
1989), 30-G12 (anti-mouse 12000 (Ledbetter and Herzenberg, 1982),
FD441.8 (anti-mouse LFA-la, CDlla) (Sarmiento et al., 1982), MJ-64
(anti-mouse CD44), or media (107 cells/nil) for 30 min and then washed
before the assay.
Construction ofCellLinesPlermanently Transfected
with LECAM-1
A cDNA clone encoding LECAM-1 was obtained from a mouse mesenteric
lymph node library by polymerase chain reaction amplification. The
LECAM-1 gene was inserted downstream of the hCMV promoter in
pMRBl01 (a derivative of EEb which contains the Escherichia coli gpt
gene) (Mulligan and Berg, 1981; Stephens and Cockett, 1989). DNA was
introduced into Ll-2 cells by electroporation (250 V, 1,180 JA Farads) and
the cells selected for resistance to mycophenolic acid. A population ofcells
staining brightly with MEL-14 were selected by fluorescence activated cell
sorting and cloned by limiting dilution. These cells, LI-2/pMRB112 (Ll-
2LECAM-) and cells transfected with the parent vector alone, Ll-
2/pMRB101 (Ll-2`°~ were tested for binding to PNAd as described
above, except that slides with cells bound were placed directly into fixative
without washing. Except for LECAM-1 expression, the phenotypes of Ll-
2LECAM-l and LI-2waor cells are similar (1200+, LFAl', and CD44-) . In
addition, the Ll-2 cells transfected with LECAM-1, but not the parent cell
line or cells transfected with the vector alone, bind PLN HEV in frozen sec-
tions (data not shown).
344Results
Immunoprecipitation ofPNAd
Immunoisolated PNAd, prepared by mAb affinity chroma-
tography from extracts ofhuman tonsil and iodinated, con-
sists of a predominant polypeptide migrating at -105 kD,
and several less intense bands in 10% SDS-PAGE gels (Fig .
1 a, lanes a and c) . The 105-kD species (whose appearance
on SDS-PAGE ranges from 90 to 105 kD depending on gel
conditions) is also the predominant band seen in gels stained
with silver (data not shown), although in Western blots (Fig.
1 b, lane a), additional bands at 65, 90, 150, and 200 kD are
detected byMECA79 (note that the smallest immunoprecip-
itated band of45 kD is notrecognized by MECA-79 by West-
ern blotting) .
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Figure 1 . SDS-PAGEand Western
blot analysis of immunopurified
peripheral lymph node addressin
(PNAd) . (a) Lanes a and c show
iodinated samples ofPNAd, lanes
b and d show similarly treated
sample eluates from a control
column prepared with an irrele-
vant class matched control anti-
body. (b) Lanea shows a nitrocel-
lulose blot of the affinity isolated
PNAd or eluate from a control rat
IgM column (lane b) probed with
MECA-79. Samples were run on
8% (a) or 10% gels (b) under re-
ducing conditionsexcept forthose
in a, lanes c and d, which were
run under nonreducing condi-
tions . (Molecular mass markers
are Rainbow Markersfrom Amer-
sham Corp. (Arlington Heights,
IL) which, in our gel system, mi-
grate at 200, 96, 78, 50, and
31 kD) .
The MECA-79 antigen, PNAd, could direct lymphocyte ex-
travasation either by binding circulating lymphocytes, or by
a less direct mechanism such as activation of adhesion mole-
cules for distinct HEV ligands . PNAd was isolated from hu-
man tonsils by sequential wheat germ agglutinin and anti-
body affinity chromatography and adsorbed onto glass
slides . PNAd coated wells bound lymphocytes avidly (Fig .
2 a) . In contrast, lymphocytes bound poorly to wells coated
with serum or with control membrane proteins, including
humanCD44 (Fig . 2 b), murine CD44, andmouse orhuman
LECAM-1 homing receptors (not shown) . Pretreatment of
the PNAd coated wells with mAb MECA-79 blocked lym-
phocyte attachment (Fig. 3), while control antibodies had no
Figure2. Binding ofmouselymphocytes
to (a) immobilized peripheral lymph
node addressin, or (b) control protein,
H-CAM (CD44) .Figure 3. Binding of lympho-
cytes to PNAd is blocked by
antibody MECA-79 against
PNAd. Experiments wereper-
formed as described in Mate-
rials and Methods with immo-
bilized PNAd and H-CAM, as
control. Six 100x fields were
counted and the average num
ber of cells bound per field for each sample or condition are
reported. The results presented are from a representative experi-
ment of two to four performed with similar results. The standard
deviation of the number of cells bound per field was <30% of the
number of cells bound (n = 6 fields/sample).
effect on binding, confirming the specificity of the inter-
action.
Lymphocyte BindingAbilityofPNAd
IsCalciumDependentandAbrogatedby
Neuraminidase Treatment
Carbohydrate determinants on PLN HEV have previously
been implicated in lymphocyte attachment (Stoolman et al.,
1984, 1987; Rosen et al., 1985, 1989; Yednock et al., 1987) .
Certain anionic mono- and polysaccharides block lympho-
cyte attachment to PLN HEV in frozen sections (Stoolman
et al., 1984, 1987; Yednock et al., 1987). In addition,
neuraminidase-treated PLN frozen sections do not support
lymphocyte binding and neuraminidase treatment in vivo
selectively blocks lymphocyte trafficking to PLN (Rosen et
al., 1985, 1989) . These effects couldbe due to charge effects
on HEV, alteration of accessory mechanisms, or a direct ef-
fect on the HEV ligand. As shown in Fig. 4 a, treatment of
immobilized PNAd with Kbrio cholera neuraminidase com-
pletely prevents lymphocyte binding. The inclusion of the
buffer
neuraminidase
" + sialyllactose
b
medium
EGTA
EGTA +Ca`
0 100 200
cells bound per t00x field
0 100 200 300 400
cells bound per 100x field
200 400 600
cells bound per 100x field
Figure 4. Binding of lymphocytes to PNAd is blocked by neuramin-
idasetreatment of PNAd (a) and is calcium dependent (b). Experi-
ments were carried out as described in Materials and Methods with
immobilized PNAd or H-CAM as control. Data were treated and
reported as in Fig. 3.
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sialidase inhibitor sialyllactose blocks the effect ofthe neura-
minidase. This suggests that the ability of neuraminidase to
block lymphocyte-HEV interactions is due to a direct effect
on PNAd itself and that the interaction of lymphocytes with
PNAd involves sialic acid residues. Interestingly, the MECA-
79 epitope on PNAd is not affected by neuraminidase treat-
ment (data not shown) .
Like lymphocyte attachment to HEV in PLN frozen sec-
tions, binding oflymphocytes to PNAd requires calcium, as
preincubation of lymphocytes with EGTA inhibits theirabil-
ity to bind isolated PNAd, while addition of calcium restores
it (Fig. 4 b).
PNAdSelectivelyBindsLymphoidCellsThatCan
Bind toPLNHEV
As the original identification of tissue-specific lympho-
cyte-HEV interactions was based on lymphoid cell lines of
restricted binding specificities, we next compared the bind-
ing of cell lines that bind well to PLN HEV with that ofcells
that bind selectively to mucosal HEV, or cell lines which do
not bind HEV (Fig. 5). Two variants of the human Jurkat T
cell line (generously provided by Lloyd Stoolman, Univer-
sity of Michigan) have been generated which differ dramati-
cally in their expression of LECAM-1 and their capacity to
adhere to PLN HEV (Stoolman and Ebling, 1989) . Only the
high binding cell line, JS-978, which expresses high levels
of LECAM-1, was able to adhere to isolated PNAd. The
mouse lymphoma cell line, 3803,an avid PLN HEV-selec-
tive binder (Gallatin et al., 1983), which expresses high lev-
els of mouse LECAM-1, also bound well to PNAd. In con-
trast, cell linesthat express little ifany LECAM-1, including
the mucosal HEVbinding cell lines TKJ43 and TKl and the
HEV nonbinding Ll-2 (Butcher et al., 1980; Gallatin et al.,
1983) cell line, did not bind to isolated PNAd, although in
parallel experiments TKJ43 and TK1 bound well to isolated
mucosal addressin (datanotshown). These experimentsdem-
onstrate the specificity of PNAd for lymphocyte cell lines
which express high levels of LECAM-1 and bind PLN HEV.
PNAdIs a CountereceptorforLECAM1
Lymphocyteinteractions with PLN HEV involve the periph-
38C13
TK1
TKJ43
L1-2
JS-978
JS-10
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relative adherence ratio
(cells bound/mouse lymphocyte bound)
Figure 5. Binding of cell lines to PNAd. Cell lines were tested for
theirbindingto PNAd asdescribed in Materials and Methods. Each
cell linewas tested two to fourtimes with similar results. Data from
representative experiments were normalized to that of mouse lym-
phocytes (binding of mouse lymphocytes ranged from 173 to 570
cells/100x field for theseexperiments). Binding to control protein
(human H-CAM/CD44) by thesecell lines ranged from one to two
cells/100x field.a
Ab treatment
medium
DREG-56
Hermes-3
b
Ab treatment
a LPAM-1
MJ-64
MEL-14
medium
0 100 200
cells bound per 100x field
. PNAd
control
cells bound per 100x field
Figure 6. Human PBMC (a) or mouse lymphocyte (b) adherence
to PNAd is blocked by mAbs against the PLN homing receptor,
LECAM-1. Lymphocytes were pretreated with mAbs andtested for
PNAd binding as described in Materials and Methods. In b, the
control used wasH-CAM (CD44). Data were treated and reported
as for Fig. 3.
eral lymph node homing receptor LECAM-1, defined by the
monoclonal antibodies MEL-14 in themouse and DREG-56,
Leu-8, andothers in thehuman(Gallatinet al., 1983 ;Tedder
et al ., 1989; Camerini et al., 1989; Kishimoto et al., 1990).
Anti-LECAM-1 antibodies that inhibit lymphocyte-HEV
interactions were tested fortheirability to blocklymphocyte
binding to isolated human PNAd. Human lymphocyte bind-
ing to PNAd was completely blocked by pretreatment of the
cellswith DREG-56 (Fig. 6a), andmouselymphocyte bind-
ing was blocked by pretreatment with MEL-14 (Fig. 6 b) .
Binding was notinhibitedby antibodies againsttheleukocyte
common antigen, T200 (CD45), or againstmouseor human
CD44, including Hermes-3 which blocks human lympho-
cyte attachment to Peyer'spatchHEV (Jalkanenet al., 1987).
Antibody to LFA-1 (CD1la/CD18) hadaslight butreproduc-
ible blocking effect on binding to PNAd . Antibody RI/2 to
the mouse integrin oi4 chain, which inhibits lymphocyte
binding to Peyer's patch but not PLN HEV in vitro (Holz-
mann et al., 1989), also failed to influence binding to puri-
fied PNAd. In contrast to its inhibitory effect on binding to
PNAd, MEL-14 had no effect on mouse lymphocyte adhe-
sion to purified MAd (datanotshown) . Thenearly complete
inhibition of PNAd binding by antibodies to LECAM-1 sug-
gests that LECAM-1 either binds PNAd or is physically or
functionally associated with a PNAd receptor on lympho-
cytes.
To examine the LECAM-1-PNAd interaction directly,
the mouse pre-B cell line, Ll-2, (which does not express
LECAM-1, Gallatin et al., 1983) wastransfected with cDNA
encoding mouse LECAM-1 and the transfectants tested for
Berg et al. The Human Peripheral Lyntph Node Vascular Addressin
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0 20 40 60
cells bound per 100x field
Figure 7. Mouse L1-2 cells
transfected with LECAM-1
cDNA bind to PNAd. Experi
El control
￿
ment was carried out as de-
scribed in Materials andMeth-
ods with immobilized PNAd
or control protein H-CAM
(CD44). Data were treated
and reported as in Fig. 3.
their PNAd-binding capacity. As seen in Fig. 7, Ll-2 cells
transfected with cDNA containing the LECAM-1 gene, Ll-
2LECAM-I but not Ll-2 cells transfected with the vector
alone, Ll-2v- ,o,, bound specifically to isolated PNAd ad-
sorbed onto glass slides. These results indicate that the pe-
ripheral lymphnode addressin is aligand forLECAM-1, the
peripheral lymph node homing receptor.
The results presented here demonstrate that the peripheral
lymph node addressin mediates lymphocyte attachment
through LECAM-1, and suggest that carbohydrate deter-
minants on one or more of the PNAd species, including
neuraminidase-sensitive sialic acid residues, comprise an
important part of thephysiological ligand(s) for LECAM-1.
A number of glycoprotein species of distinct molecular
weights bear the anti-PNÀd mAb MECA-79 epitope; the
predominant iodinated species is -105 kD under reducing
and nonreducingconditions. In the mouse, MECA-79recog-
nizes a similar pattern of species by Western blot, with two
predominant glycoproteins of 90 and 115 kD, a minor65-kD
species, and additional species reproducibly detected at 75,
170, and 200 kD (Berg, E., P Streeter, and E. C. Butcher,
manuscript in preparation) . Interestingly, in the mouse,
MECA-79 also reacts with an ti50-kD species that incor-
porates 11SO4 (metabolically labeledby incubation of lymph
node fragments), but labels poorly if at all with iodine. In
independent studies, Rosen and co-workers have confirmed
that this component of mouse PNAd is also a ligand for
LECAM-1. It is precipitated by a chimeric antibody contain-
ing LECAM-1 and the hinge and constant regions of the hu-
man immunoglobulin heavy chains (Watson et al ., 1990), as
is the dominant 105-kD major PNAd polypeptide described
here (Berg, E., unpublished results). It remains to be deter-
mined which molecular species identified by MECA-79 rep-
resent the dominant LECAM-1 binding elementor elements;
whetherone, a subset, or all can interact with the lectin; and
whether any functionally significant species recognized by
LECAM-1 lack the MECA-79 epitope. However, our results
raise the possibility that both the MECA-79 epitope and
LECAM-1 bindingability are determined notprimarily by a
single glycoprotein species or receptor, but rather by unique
PLNHEVspecific glycosyltransferases or othermechanisms
of posttranslational modification that can decorate more than
one HEV surface acceptor molecule with mAb MECA-79
and/or LECAM-1 binding sites.
This modelis consistent with theknownimportance of the
lectin domain ofLECAM-1 in recognition of HEV, and with
our emerging understanding of the structure/function rela-
tionships of carbohydrate ligands of two related lectins in-volved in leukocyte-endothelial cell interactions, SLAM-1
and GMP-140. These molecules are members of a subfamily
ofC-type (calcium-dependent) lectins, the LEC-CAMs or se-
lectins, characterized structurally by an N112-terminal do-
main homologous to C-type lectins, an epidermal growth
factor-like domain, a variable number of repeating units re-
lated to complement regulatory sequences, a transmembrane
domain and a short cytoplasmic tail (Siegelmanet al., 1989;
Lasky etal., 1989; Tedder et al ., 1989 ; Camerini eta1.,19ß9 ;
Bevilacqua et al., 1989 ; Johnston et al., 1989) . The lectin
domains of these molecules are important to their function.
Recognition of neutrophils by GMP-140 and ELAM-1, like
recognition ofPNAd by LECAM-1, is calcium dependent and
sensitive to ligand treatment with neuraminidase (Phillips et
al., 1990; Walz et al., 1990; Corral et al., 1990; Moore et
al., 1991; Berg, E., personal observations) . A major neutro-
phil carbohydrate ligand for ELAM-1 has been identified as
the sialated Lewis X antigen, sLex (Lowe et al., 1990 ; Phil-
lips et al ., 1990; Walz et al., 1990), and neuraminidase-sen-
sitive determinants, perhaps associated with the Lewis X
antigen itself, Lex, have been implicated as ligands for GMP-
140 (Larsen et al., 1990; Corral et al ., 1990; Moore et al.,
1991). SLex and Lex are knownto modify multiple glycopro-
tein species as well as glycolipids on neutrophils and the ex-
pression of these carbohydrate determinants by neutrophils
may be determined, in part, by expression of a specific alpha
(1,3) fucosyltransferase (Goelz et al., 1990). It is attractive
to hypothesize thatthe mAb MECA-79 may recognize a sialic
acid-independent carbohydrate structure whose expression
is conferred by a PLN HEV-specific glycosyltransferase or
other carbohydrate-modifying enzyme, and that comprises
the core of the sialic acid-modified LECAM-1 recognition
site. It is also possible, however, that the LECAM-1 ligand
is an independent carbohydrate structure expressed in close
proximity to the MECA-79 epitope.
It is worth noting that sLex and Lex are unlikely to be nat-
ural HEV ligands for LECAM-1 as HEV do not express ap-
preciablelevels ofeither antigen, atleastwhen examined with
specific monoclonal antibodies. Furthermore, monoclonal
anti-sLex, which inhibits neutrophil adhesion to ELAM-1
cDNA transfectants, has no effect on lymphocyte binding
to isolated PNAd (Berg, E., and T. Yoshino, unpublished
results) .
In addition to PNAd, two other vascular addressins have
been identified. The mucosal addressin (MAd) is a 60-kD
glycoprotein involved in trafficking of mucosa-homing lym-
phocytes and is preferentially expressed on HEV in mucosal
lymphoid tissues and venules within the gut lamina propria
(Streeter et al ., 19ß8a). Like PNAd, MAd is an adhesion
molecule for lymphocytes, however, it selectively binds lym-
phocytes and lymphoid cell lines that interact with mucosal
HEV (Nakache et al., 1988). ELAM-1, first characterized as
an inducible endothelial cell adhesion molecule for neutro-
phils (Bevilacqua et al., 1987), plays a second role as a skin
vascular addressin. In the setting of chronic inflammation,
it is preferentially expressed in cutaneous sites, and it selec-
tively binds a skin-associated memory T cell subset defined
by expression of the cutaneous lymphocyte antigen (Picker
et al., 1990a, 1991) . Thus, the importance of the LEC-
CAM/selectin gene family to lymphocyte traffic is under-
scored by the involvement of two of its members, LECAM-1
The Journal of Cell Biology, Volume 114, 1991
and ELAM-1, in tissue specific lymphocyte-endothelial cell
recognition.
In conclusion, our results define a tissue-specific endothe-
lial cell adhesion mechanism capable of directing the traffic
of lymphocytes in man, and suggest that this mechanism in-
volves a lectin-carbohydrate interaction between LECAM-1
and one or more species immunoisolated with the PNAd-
specific mAb, MECA-79.
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